Add BrightSurf on Google Email

WVU researchers working to get people with hip pain moving

A WVU researcher is working on a biopsychosocial intervention to help people with chronic hip pain move and regain mobility. The intervention, called HIPS, combines mindfulness techniques like self-compassion and progressive relaxation with goal-setting and diaphragmatic breathing to reduce pain and increase physical activity.

SourceWest Virginia University·DateMar 23, 2023
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.

Potential relief for osteoarthritis moves to clinical trial after animal studies

Researchers have found a potential treatment for osteoarthritis by targeting the GP130 immune receptor, which causes hyper-inflammation in joints. The new compound R805/CX-011 showed promising results in animal studies, reducing joint pain and stiffness, and may lead to Phase 1 and 2A clinical trials.

SourceKeck School of Medicine of USC·JournalScience Translational Medicine·TypeExperimental study·DateMar 22, 2023

Study shows physical activity prevents, not just delays, cancer recurrence in patients previously treated for colon cancer

Researchers found that physical activity can prevent cancer recurrence in stage III colon cancer patients by lowering the recurrence rate within the first year of treatment. This association persisted for approximately three years after surgery, suggesting a long-term survival benefit.

SourcePennington Biomedical Research Center·JournalBritish Journal of Sports Medicine·TypeRandomized controlled/clinical trial·DateMar 21, 2023

Can lymph nodes boost the success of cancer immunotherapy?

Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.

SourceUniversity of California - San Francisco·JournalCell·DateMar 20, 2023

Real-world studies confirm effectiveness of bulevirtide to treat chronic hepatitis D

Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.

SourceElsevier·JournalJournal of Hepatology·TypeExperimental study·DateMar 20, 2023

Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer

A Phase II trial led by researchers from the University of Texas MD Anderson Cancer Center demonstrated that adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage non-small cell lung cancer. The treatment also...

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Medicine·DateMar 16, 2023
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Breakthrough drug combination remains safe and effective in patients with cystic fibrosis after four years

A multicenter study found that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years while maintaining previously achieved clinical improvement. This breakthrough therapy has improved the quality and length of patients' lives, with some even seeing a 15% increase in lung function.

SourceMedical University of South Carolina·JournalJournal of Cystic Fibrosis·TypeRandomized controlled/clinical trial·DateMar 15, 2023

AJR on a decade of lung cancer screening in American newspapers

A study of US newspaper articles found that lung cancer screening was generally positively covered between 2010 and 2022. However, crucial aspects such as enrollment criteria and cost issues were frequently omitted, highlighting a need for radiologists to take an active role in media coverage.

SourceAmerican Roentgen Ray Society·JournalAmerican Journal of Roentgenology·TypeImaging analysis·DateMar 15, 2023

COVID-19 discovery could protect high-risk patients

UVA researchers discovered a metabolic pathway that can modulate COVID-19 inflammation, lung recovery, and host metabolic health. They suggest a potentially viable therapeutic agent that may be combined with existing anti-viral agents to treat severe COVID-19 in patients with underlying metabolic disease.

SourceUniversity of Virginia Health System·JournalScience Immunology·DateMar 14, 2023
Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows

The ProtecT trial found that active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see their cancer progress, but this didn't reduce their likelihood of survival.

SourceEuropean Association of Urology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 11, 2023

New technique reduces postoperative complications in prostate cancer surgery

A new technique involving a small flap in the peritoneum can reduce postoperative complications in prostate cancer surgery by allowing lymphatic fluid to escape and be absorbed. The study found that this technique significantly reduced the incidence of lymphocele, a common complication where lymphatic fluid collects in the pelvis.

SourceEuropean Association of Urology·DateMar 11, 2023

Urine gene test can predict bladder cancer years before diagnosis

A new urine gene test can detect genetic mutations in urine that predict bladder cancer up to 12 years in advance of clinical symptoms. The test was trialled on over 50,000 participants and showed promising results, suggesting its potential for early detection and reduced unnecessary invasive procedures.

SourceEuropean Association of Urology·DateMar 10, 2023

Advanced imaging may help in clinical treatment of prostate cancer

A trial using PSMA-PET/CT scans has shown that clinicians changed their treatment plans for patients with clinically significant prostate cancer in 19% of cases, helping to detect more cancers. The technique was found to be beneficial in high-risk patients but also led to false positives requiring further investigations.

SourceEuropean Association of Urology·DateMar 9, 2023

McMaster researchers trial potential hemophilia treatment

A global study involving McMaster University researchers has trialled a potential new treatment for hemophilia A, a life-threatening genetic blood disorder. Once-weekly injections of efanesoctocog alfa can prevent bleeding and promote near-normal activity by the clotting agent factor VIII.

SourceMcMaster University·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 9, 2023
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Nirogacestat, a new desmoid tumor treatment, improves outcomes for people with sarcoma

A new clinical trial has shown promising results for nirogacestat, a targeted drug that blocks the Notch protein. In the Phase 3 trial, 41% of patients' tumors significantly shrank after taking nirogacestat, with no growth in over 75%. The most common side effects were fatigue, gastrointestinal problems, and skin rashes.

SourceMemorial Sloan Kettering Cancer Center·JournalNew England Journal of Medicine·DateMar 9, 2023

New approach to improving clinical trial enrollment and diversity

A new approach by the Medical University of South Carolina aims to increase clinical trial participation, especially from diverse populations. By making patients eligible for research opportunities by default, while allowing opt-out, the team saw a significant increase in potential participants.

SourceMedical University of South Carolina·JournalJournal of Clinical and Translational Science·TypeObservational study·DateMar 8, 2023

AI-powered ultrasound imaging that detects breast cancer

A team of POSTECH researchers has developed a deep learning-based multimodal fusion network for segmentation and classification of breast cancers using B-mode and strain elastography ultrasound images. The method achieved high accuracy in distinguishing benign from malignant lesions, outperforming conventional methods.

SourcePohang University of Science & Technology (POSTECH)·JournalBioengineering & Translational Medicine·DateMar 8, 2023
Rigol DP832 Triple-Output Bench Power Supply

Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.

Digital rectal examination is not useful to early detect prostate cancers

A new study suggests that digital rectal examination (DRE) is not a reliable screening tool for early prostate cancer detection. Researchers found that DRE missed many cancers in their early stages, with only 3 out of 57 suspicious cases detected. This method was compared to PSA testing, which detected four times more prostate cancers.

SourceEuropean Association of Urology·DateMar 8, 2023

CNIO researchers propose biomarkers to select breast cancer patients who could benefit from denosumab treatment

Researchers have identified a biomarker that can select breast cancer patients who may benefit from denosumab treatment. The study found that tumors with high RANK protein expression are associated with poor prognosis and response to chemotherapy, suggesting that denosumab may be effective in hormone-receptor negative tumors.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalEMBO Molecular Medicine·TypeObservational study·DateMar 7, 2023

Octapharma USA research at AAAAI: cutaquig® study at higher infusion rates presented

A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.

SourceYankee Public Relations·JournalJournal of Allergy and Clinical Immunology·TypeObservational study·DateMar 6, 2023

The Access to Advanced Health Institute reports encouraging results of first-in-human trial of its temperature-stable tuberculosis vaccine candidate

A Phase 1 clinical trial of AAHI's thermostable, freeze-dried single-vial ID93 + GLA-SE vaccine candidate showed higher levels of antibodies and favorable cellular immune responses compared to the two-vial presentation. The results represent significant progress in global efforts to combat TB.

SourceAccess to Advanced Health Institute·JournalNature Communications·TypeRandomized controlled/clinical trial·DateMar 6, 2023
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

High-dose anticoagulation can reduce intubations and improve survival for hospitalized COVID-19 patients

High-dose anticoagulation reduces intubations and deaths by 30% in hospitalized COVID-19 patients, especially those with ARDS. The study found a significant reduction in mortality and need for ICU care among patients treated with therapeutic anticoagulation.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateMar 6, 2023

Mass General Brigham study finds virtual care team strategy improved treatment for heart failure patients

A virtual care team consisting of physicians and pharmacists improved the adoption of life-saving therapies in patients with heart failure, leading to increased use of evidence-based treatments and better patient outcomes. The strategy was safe and effective, with comparable length of stay and safety events between the groups.

SourceMass General Brigham·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateMar 6, 2023

Temperature-stable TB vaccine safe, prompts immune response in NIH-supported study

A Phase 1 trial of a thermostable tuberculosis (TB) vaccine candidate found it to be safe and stimulated both antibodies and cellular responses. The vaccine, ID93+GLA-SE, was well-tolerated and produced higher levels of antibodies in recipients compared to a non-thermostable formulation.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalNature Communications·DateMar 6, 2023

Transcatheter Mitral Valve Repair Safe and Effective in Real World Setting

The study found that transcatheter edge-to-edge repair achieved a successful repair for nearly 9 out of 10 patients and reduced valve leakage from severe to moderate or less in almost 90% of patients. Patients who underwent the procedure were half as likely to die within one year compared with those in whom the procedure was unsuccessful.

SourceAmerican College of Cardiology·DateMar 5, 2023
GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

Transcatheter mitral valve repair in heart failure patients significantly reduces hospitalizations and improves survival

A new study shows that transcatheter mitral valve repair significantly reduces hospitalizations by almost 50 percent and death by nearly 30 percent in heart failure patients with severe mitral regurgitation. The procedure, using Abbott's MitraClip system, improves symptoms, reduces hospitalizations, and leads to longer survival.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 5, 2023

Innovative technology shows great promise against certain head and neck cancers

Researchers have developed a microfluidic squeezing technology that stimulates anti-tumor activity in a subtype of HPV16-positive head and neck, cervical, and anal cancers. The treatment uses peripheral blood mononuclear cells trained to recognize and attack cancer cells without genetic modifications.

SourceUniversity of Colorado Anschutz Medical Campus·JournalInvestigational New Drugs·TypeRandomized controlled/clinical trial·DateMar 3, 2023

AI used to predict future flares of ulcerative colitis activity

Researchers at University of Birmingham develop AI diagnostic tool to predict ulcerative colitis flare-ups with 89% accuracy. The system identifies markers of inflammation and healing, providing analytical support for clinicians in managing the disease.

SourceUniversity of Birmingham·JournalGastroenterology·TypeExperimental study·DateMar 3, 2023

Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.

SourceUniversity of Chicago Medical Center·JournalClinical Cancer Research·TypeExperimental study·DateMar 2, 2023
Creality K1 Max 3D Printer

Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.

HKUMed discovers using real-world data that the newest glucose-lowering drug could reduce the risks of renal and respiratory diseases

A retrospective cohort study found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduced the risk of end-stage renal disease, obstructive airway disease, and pneumonia in patients with type 2 diabetes. SGLT2i may be a better alternative to dipeptidyl peptidase-4 inhibitors for extra-glycaemic protection.

SourceThe University of Hong Kong·JournalJAMA Network Open·TypeExperimental study·DateMar 2, 2023

Review finds fledgling chronic back pain therapy needs more rigorous study

A systematic review of Cognitive Functional Therapy found it to be no better than traditional therapies in reducing pain and disability in people with chronic low back pain. The researchers call for future trials featuring blinded participants and larger sample sizes to improve current evidence.

SourceUniversity of New South Wales·JournalJournal of Orthopaedic and Sports Physical Therapy·TypeSystematic review·DateMar 1, 2023
Apple iPad Pro 11-inch (M4)

Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.

CU School of Medicine researchers part of national team that identified a new dietary approach to treatment for eosinophilic esophagitis

A new dietary approach has been identified to treat eosinophilic esophagitis by eliminating only dairy products, showing similar effectiveness to the standard six-food elimination diet. This breakthrough study led by CU School of Medicine researchers offers a more patient-friendly treatment option with fewer drawbacks.

SourceUniversity of Colorado Anschutz Medical Campus·JournalThe Lancet Gastroenterology & Hepatology·DateFeb 28, 2023

Alternative bladder cancer treatment emerges amid worldwide shortage of standard of care BCG

A new study finds that a combination of chemotherapy drugs performs better than BCG in preventing high-grade cancer recurrence in patients with non-muscle invasive bladder cancer. This alternative treatment has shown excellent safety and efficacy outcomes, providing a viable option for patients facing a shortage of standard care treatm...

SourceUniversity of Iowa Health Care·JournalJAMA Network Open·TypeData/statistical analysis·DateFeb 28, 2023

The Texas Heart Institute delivers a new first in heart failure treatment using cell therapy

A new cell therapy has demonstrated significant benefits in improving the heart's pumping ability and reducing the risk of cardiovascular death, heart attack, or stroke in patients with chronic heart failure. The therapy, using mesenchymal precursor cells (MPCs), also showed a strong signal in reducing inflammation and improving microv...

SourceTexas Heart Institute·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateFeb 27, 2023

Forgoing one food treats eosinophilic esophagitis as well as excluding six

A new study found that eliminating animal milk alone from the diet of adults with eosinophilic esophagitis is just as effective as eliminating six common foods, including animal milk, eggs, wheat, soy, fish, and nuts. The one-food elimination diet may be a more manageable option for people with EoE.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalThe Lancet Gastroenterology & Hepatology·DateFeb 27, 2023
Apple MacBook Pro 14-inch (M4 Pro)

Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.

New study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE)

Researchers found that IVC filters were effective in preventing pulmonary embolisms (PE) in patients with deep vein blood clots, even when used prophylactically. Approximately half of the patients had their filters removed without complication or recurrence of DVT or PE.

SourceSociety of Interventional Radiology·JournalJournal of Vascular and Interventional Radiology·TypeRandomized controlled/clinical trial·DateFeb 23, 2023

ESMO Targeted Anticancer Therapies Congress 2023

The ESMO Targeted Anticancer Therapies Congress 2023 features presentations on drug discovery and development for various targets, precision medicine, and early clinical trial methodology. Keynote lectures highlight novel insights in mutational signatures and epigenetic therapies.

SourceEuropean Society for Medical Oncology·DateFeb 23, 2023
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

U.S. study of intravenous mistletoe extract to treat advanced cancer

Researchers found that dose escalation to 600mg of ME improved disease control in five patients, while stable disease was observed in another five patients with an average duration of 15 weeks. Additionally, patients reported overall improved quality of life via a questionnaire.

SourceJohns Hopkins Medicine·JournalCancer Research Communications·DateFeb 22, 2023
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.

Parkinson’s disease patients experience significant reduction in symptoms with non-surgical focused ultrasound treatment

A new study led by University of Maryland School of Medicine researchers found that focused ultrasound treatment significantly reduced tremors and improved mobility in Parkinson's patients. Nearly 70% of treated patients showed a successful response after three months, with two-thirds continuing to respond a year later.

SourceUniversity of Maryland School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateFeb 22, 2023

Symptom and viral rebound uncommon after untreated COVID-19 infection

Researchers found that a combination of symptom and high-level viral rebound after untreated COVID-19 infection is rare, occurring in only 3 percent of study participants. This suggests that accounting for underlying rates of symptom relapse is crucial when evaluating antiviral treatment effects.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateFeb 20, 2023
Meta Quest 3 512GB

Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.

Tuberculosis patients see dramatic cut in treatment duration, treatment effectiveness remains

A groundbreaking study found that a new TB treatment strategy can shorten treatment duration while maintaining effectiveness. The TRUNCATE-TB trial showed that an initial 8-week treatment period followed by retreatment for those not cured was as effective as the standard 6-month treatment but halved the average total time on treatment.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateFeb 20, 2023
GoPro HERO13 Black

GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.

ACTG to make 29 presentations at CROI 2023

The AIDS Clinical Trials Group (ACTG) will present 29 presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023. The studies focus on COVID-19, HIV cure, pathogenesis, treatment, long-term complications, tuberculosis, hepatitis C, and contraception.

SourceAIDS Clinical Trials Group·DateFeb 14, 2023
Nikon Monarch 5 8x42 Binoculars

Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.